Search Results - "S. Mook"

Online adaptive MR-guided radiotherapy for rectal cancer; feasibility of the workflow on a 1.5T MR-linac: clinical implementation and initial experience by Intven, M.P.W., de Mol van Otterloo, S.R., Mook, S., Doornaert, P.A.H., de Groot-van Breugel, E.N., Sikkes, G.G., Willemsen-Bosman, M.E., van Zijp, H.M., Tijssen, R.H.N.

“…•MR-guided radiotherapy for rectal cancer on a 1.5T MR-linac is feasible.•An online adaptive workflow takes about 48 min each fraction.•Treatment of rectal…”
Get full text

Successful pregnancy outcome under prolonged ustekinumab treatment in a patient with Crohn's disease and paradoxical psoriasis by Galli-Novak, E., Mook, S.-C., Büning, J., Schmidt, E., Zillikens, D., Thaci, D., Ludwig, R.J.

Get full text

Endobronchial Ultrasonography to Assess and Evaluate Tracheobronchial Tree Invasion in cT4b Esophageal Cancer Patients Treated with Definitive Chemoradiotherapy: Assessment of Resectability by Defize, I L, de Groot, E M, van de Langerijt, O, van Velzen, M, Mook, S, Haj Mohammad, N, Bulbul, M, Ruurda, J P, van Hillegersberg, R

“…In cT4b esophageal cancer, accurate assessment of tracheobronchial tree invasion after definitive chemoradiotherapy (dCRT) aids in the selection of patients…”
Get full text

The 70-gene prognosis signature predicts early metastasis in breast cancer patients between 55 and 70 years of age by Mook, S., Schmidt, M.K., Weigelt, B., Kreike, B., Eekhout, I., van de Vijver, M.J., Glas, A.M., Floore, A., Rutgers, E.J.T., van ‘t Veer, L.J.

“…The majority of breast cancer patients are postmenopausal women who are increasingly being offered adjuvant chemotherapy. Since the beneficial effect of…”
Get full text

Technical feasibility of magnetic resonance fingerprinting on a 1.5T MRI-linac by Bruijnen, T, van der Heide, O, Intven, M P W, Mook, S, Lagendijk, J J W, van den Berg, C A T, Tijssen, R H N

“…Hybrid MRI-linac (MRL) systems enable daily multiparametric quantitative MRI to assess tumor response to radiotherapy. Magnetic resonance fingerprinting (MRF)…”
Get more information

Salvage Robot-Assisted Minimally Invasive Esophagectomy (RAMIE) for T4b Esophageal Cancer After Definitive Chemoradiotherapy by Defize, I. L., van der Horst, S., Bülbul, M., Haj Mohammad, N., Mook, S., Meijer, G. J., Brosens, L. A. A., Ruurda, J. P., van Hillegersberg, R.

“…Background Patients  with esophageal cancer  that invades adjacent structures (cT4b) are precluded from surgery and usually treated with definitive…”
Get full text

Safety and Feasibility of Robot-Assisted Minimally Invasive Esophagectomy (RAMIE) with Three-Field Lymphadenectomy and Neoadjuvant Chemoradiotherapy in Patients with Resectable Esophageal Cancer and Cervical Lymph Node Metastasis by van der Horst, S., Weijs, T. J., Braunius, W. W., Mook, S., Mohammed, N. Haj, Brosens, L., van Rossum, P. S. N., Weusten, B. L. A. M., Ruurda, J. P., van Hillegersberg, R.

“…Background In the West, patients with cervical lymph node metastasis of resectable esophageal cancer at diagnosis are generally precluded from curative…”
Get full text

ASO Visual Abstract: Safety and Feasibility of Robot-Assisted Minimally Invasive Esophagectomy (RAMIE) with Three-Field Lymphadenectomy and Neoadjuvant Chemoradiotherapy in Patients with Resectable Esophageal Cancer and Cervical Lymph Node Metastasis by van der Horst, S., Weijs, T. J., Braunius, W. W., Mook, S., Mohammed, N. Haj, Brosens, L., van Rossum, P. S. N., Weusten, B. L. A. M., Ruurda, J. P., van Hillegersberg, R.

Get full text

Diagnostic performance of MRI for assessment of response to neoadjuvant chemoradiotherapy in oesophageal cancer by Vollenbrock, S. E., Voncken, F. E. M., van Dieren, J. M., Lambregts, D. M. J., Maas, M., Meijer, G. J., Goense, L., Mook, S., Hartemink, K. J., Snaebjornsson, P., ter Beek, L. C., Verheij, M., Aleman, B. M. P., Beets‐Tan, R. G. H., Bartels‐Rutten, A.

“…Background Patients with a pathological complete response (pCR) after neoadjuvant chemoradiotherapy (nCRT) for oesophageal cancer may benefit from non‐surgical…”
Get full text

CTV-to-PTV margin assessment for esophageal cancer radiotherapy based on an accumulated dose analysis by Boekhoff, M.R., Defize, I.L., Borggreve, A.S., van Hillegersberg, R., Kotte, A.N.T.J., Lagendijk, J.J.W., van Lier, A.L.H.M.W., Ruurda, J.P., Takahashi, N., Mook, S., Meijer, G.J.

“…•The smallest clinical target volume (CTV) to planned target volume (PTV) margins that yielded full dosimetric coverage for esophageal cancer radiotherapy were…”
Get full text

3-Dimensional target coverage assessment for MRI guided esophageal cancer radiotherapy by Boekhoff, M.R., Defize, I.L., Borggreve, A.S., Takahashi, N., van Lier, A.L.H.M.W., Ruurda, J.P., van Hillegersberg, R., Lagendijk, J.J.W., Mook, S., Meijer, G.J.

“…•Online MR-guided soft-tissue registration protocols exhibited modest improvements of the geometric target coverage probability as compared to online…”
Get full text

Clinical implementation and feasibility of long-course fractionated MR-guided chemoradiotherapy for patients with esophageal cancer: An R-IDEAL stage 1b/2a evaluation of technical innovation by Boekhoff, M.R., Bouwmans, R., Doornaert, P.A.H., Intven, M.P.W., Lagendijk, J.J.W., van Lier, A.L.H.M.W., Rasing, M.J.A., van de Ven, S., Meijer, G.J., Mook, S.

“…•Online MR-guided long-course fractionated chemoradiotherapy for patients with esophageal cancer was feasible in 7 out of 9 patients.•Median treatment time was…”
Get full text

ypT0N+ status in oesophageal cancer patients: Location of residual metastatic lymph nodes with regard to the neoadjuvant radiation field by Schurink, B., Seesing, M.F.J., Goense, L., Mook, S., Brosens, L.A.A., Mohammad, N. Haj, Ruurda, J.P., Roeling, T.A.P., Bleys, R.L.A.W., van Hillegersberg, R.

“…A subset of oesophageal cancer patients has residual nodal disease despite complete pathologic response of the primary tumour after neoadjuvant chemoradiation…”
Get full text

Additional prognostic value of the 70-gene signature (MammaPrint® ) among breast cancer patients with 4–9 positive lymph nodes by Saghatchian, M, Mook, S, Pruneri, G, Viale, G, Glas, A.M, Guerin, S, Cardoso, F, Piccart, M, Tursz, T, Delaloge, S, van't Veer, L

“…Abstract Background The 70 gene-signature (MammaPrint® ) is a prognostic profile of distant recurrence and survival of primary breast cancer (BC). BC patients…”
Get full text

PO-0703: Perioperative chemotherapy versus neoadjuvant chemoradiotherapy for esophageal adenocarcinoma by Goense, L, Van der Sluis, P.C, Van Rossum, P.S.N, Van der Horst, S, Van Vulpen, M, Mook, S, Ruurda, J.P, Van Hillegersberg, R

Get full text

Effect of a prediction tool and communication skills training on communication of treatment outcomes: a multicenter stepped wedge clinical trial (the SOURCE trial) by van de Water, L.F., Kuijper, S.C., Henselmans, I., van Alphen, E.N., Kooij, E.S., Calff, M.M., Beerepoot, L.V., Buijsen, J., Eshuis, W.J., Geijsen, E.D., Havenith, S.H.C., Heesakkers, F.F.B.M., Mook, S., Muller, K., Post, H.C., Rütten, H., Slingerland, M., van Voorthuizen, T., van Laarhoven, H.W.M., Smets, E.M.A.

“…For cancer patients to effectively engage in decision making, they require comprehensive and understandable information regarding treatment options and their…”
Get full text

Daily clinical practice of fresh tumour tissue freezing and gene expression profiling; logistics pilot study preceding the MINDACT trial by Mook, S, Bonnefoi, H, Pruneri, G, Larsimont, D, Jaskiewicz, J, Sabadell, M.D, MacGrogan, G, van’t Veer, L.J, Cardoso, F, Rutgers, E.J

“…Abstract Purpose The 70-gene prognosis-signature is a prognostic tool for early breast cancer analysis. In addition to scientific evidence, implementation of…”
Get full text

Additional value of the 70-gene signature and levels of ER and PR for the prediction of outcome in tamoxifen-treated ER-positive breast cancer by Kok, M, Koornstra, R.H, Mook, S, Hauptmann, M, Fles, R, Jansen, M.P, Berns, E.M, Linn, S.C, Van 't Veer, L.J

“…Abstract Background Breast cancer patients with node positive disease can have an excellent outcome with tamoxifen only. It is unclear whether analysing both…”
Get full text

In vivo regulation of plasma free fatty acids in insulin resistance by Mook, S., Halkes, C.J.M., Bilecen, S., Cabezas, M.Castro

“…Elevated plasma free fatty acid (FFA) concentrations as seen in obesity, insulin resistance, and type 2 diabetes are partly caused by impaired inhibition of…”
Get full text

SP-0393: Clinical opportunities with MR guided external beam RT by Mook, S.

Get full text